How Big Can This Blockbuster Drug Get?

There are a lot investors doubting the recently created AbbVie and its blockbuster arthritis drug, Humira. That's largely because Humira makes up such an overwhelming percentage of AbbVie's earnings, and investors are watching closely to see how the company positions itself ahead of the drug's patent expiration in a few years. In this video, Motley Fool health care bureau chief Brenton Flynn discusses one of his takeaways from AbbVie's presentation at this year's JPMorgan conference on health care, highlighting some surprising areas where the company will be pushing for Humira growth.

In the pharma business, great success comes with a caveat. AbbVie is a perfect example, as investors in the new company are left wondering what the future holds once the company's golden goose, Humira, is cooked. The Fool's brand new premium report on the company answers the high-profile questions that AbbVie investors are asking, and as an added bonus, you'll receive a full year of free analyst updates as significant news hits. Simply click here now to claim your copy today.

The article How Big Can This Blockbuster Drug Get? originally appeared on

Brenton Flynn has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.